Trial Profile
A retrospective case series assessing use of telavancin in patients with methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis and prosthetic joint infection
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jul 2018
Price :
$35
*
At a glance
- Drugs Telavancin (Primary)
- Indications Methicillin-resistant Staphylococcus aureus infections
- Focus Adverse reactions; Therapeutic Use
- 29 Jul 2018 New trial record